“Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis.” Vincent Cottin and Toby Maher. Eur Respir Rev 2015; 24: 58–64.


Source: Eur Respir Rev 2015; 24: 545
Journal Issue: September
Disease area: Interstitial lung diseases

Full text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
“Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis.” Vincent Cottin and Toby Maher. Eur Respir Rev 2015; 24: 58–64.. Eur Respir Rev 2015; 24: 545

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
“Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis.” Yasuhiro Kondoh, Vincent Cottin and Kevin K. Brown. Eur Respir Rev 2017; 26: 170050.
Source: Eur Respir Rev, 27 (148) 175050; 10.1183/16000617.5050-2017
Year: 2018


“Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis.” Bridget F. Collins and Ganesh Raghu. Eur Respir Rev 2019; 28: 190022.
Source: Eur Respir Rev, 28 (154) 195022; 10.1183/16000617.5022-2019
Year: 2019


“Metabolic dysfunction in pulmonary hypertension: from basic science to clinical practice.” Stephen Y. Chan and Lewis J. Rubin. Eur Respir Rev 2017; 26: 170094.
Source: Eur Respir Rev, 27 (147) 175094; 10.1183/16000617.5094-2017
Year: 2018


“The therapy of idiopathic pulmonary fibrosis: what is next?” Vivien Somogyi, Nazia Chaudhuri, Sebastiano Emanuele Torrisi, et al. Eur Respir Rev 2019; 28: 190021.
Source: Eur Respir Rev, 28 (153) 195021; 10.1183/16000617.5021-2019
Year: 2019


“Cardiovascular disease and COPD: dangerous liaisons?” Klaus F. Rabe, John R. Hurst and Samy Suissa. Eur Respir Rev 2018; 27: 180057.
Source: Eur Respir Rev, 27 (150) 185057; 10.1183/16000617.5057-2018
Year: 2018


“Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension.” Irene M. Lang and Sean P. Gaine. Eur Respir Rev 2015; 24: 630–641.
Source: Eur Respir Rev 2015; 25: 99
Year: 2016


“Microalbuminuria as a potential novel cardiovascular biomarker in patients with COPD.” Ciro Casanova and Bartolome R. Celli. Eur Respir J 2014; 43: 951–953.
Source: Eur Respir J 2014; 43: 1825
Year: 2014


“Idiopathic inflammatory myopathies and the lung.” Jean-Christophe Lega, Quitterie Reynaud, Alexandre Belot, Nicole Fabien, Isabelle Durieu and Vincent Cottin. Eur Respir Rev 2015; 24: 216–238.
Source: Eur Respir Rev 2015; 24: 545
Year: 2015


“Central sleep apnoea and periodic breathing in heart failure: prognostic significance and treatment options.” Winfried Randerath, Oana Deleanu, Sophia Schiza and Jean-Louis Pepin. Eur Respir Rev 2019; 28: 190084.
Source: Eur Respir Rev, 28 (154) 195084; 10.1183/16000617.5084-2019
Year: 2019


“Serious bronchopulmonary involvement due to chronic lymphocytic leukaemia.” Delphine Carmier Catherine Dartigeas Julie Mankikian Cecilla Rousselot-Denis Severine Lissandre Patrice Diot, Sylvain Marchand-Adam. Eur Respir Rev 2013; 22: 416–419.
Source: Eur Respir Rev 2013; 22: 589
Year: 2013


“Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis.” Michael Kreuter, Marlies S. Wijsenbeek, Martina Vasakova, Paolo Spagnolo, Martin Kolb, Ulrich Costabel, Derek Weycker, Klaus-Uwe Kirchgaessler and Toby M. Maher. Eur Respir J 2016; 47: 1776–1784.
Source: Eur Respir J 2016; 48: 593
Year: 2016


“Umeclidinium in patients with COPD: a randomised, placebo-controlled study.” Roopa Trivedi, Nathalie Richard, Rashmi Mehta and Alison Church. Eur Respir J 2014; 43: 72–81.
Source: Eur Respir J 2014; 44: 555
Year: 2014


“Is bronchiectasis really a disease?” Michal Shteinberg, Patrick A. Flume and James D. Chalmers. Eur Respir Rev 2020; 29: 190051.
Source: Eur Respir Rev, 29 (155) 195051; 10.1183/16000617.5051-2019
Year: 2020


“Asthma inhaler adherence determinants in adults: systematic review of observational data.” Alexandra L. Dima, Gimena Hernandez, Oriol Cunillera, Montserrat Ferrer, Marijn de Bruin and the ASTRO-LAB group. Eur Respir J 2015; 45: 994–1018.
Source: Eur Respir J 2016; 47:1892
Year: 2016


“Long-term benefits of airway clearance in bronchiectasis: a randomised placebo-controlled trial.” Gerard Muñoz, Javier de Gracia, Maria Buxó, Antonio Alvarez and Montserrat Vendrell. Eur Respir J 2018; 51: 1701926.
Source: Eur Respir J, 51 (4) 1751926; 10.1183/13993003.51926-2017
Year: 2018


“Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension.” Irene Lang, Bernhard C. Meyer, Takeshi Ogo, Hiromi Matsubara, Marcin Kurzyna, Hossein-Ardeschir Ghofrani, Eckhard Mayer and Philippe Brenot. Eur Respir Rev 2017; 26: 160119.
Source: Eur Respir Rev, 26 (144) 165119; 10.1183/16000617.5119-2016
Year: 2017


“Differential diagnosis of usual interstitial pneumonia: when is it truly idiopathic?” Wim A. Wuyts, Alberto Cavazza, Giulio Rossi, Francesco Bonella, Nicola Sverzellati and Paolo Spagnolo. Eur Respir Rev 2014; 23: 308–319.
Source: Eur Respir Rev 2014; 23: 537
Year: 2014


“Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results”. Robert Wilson, Antonio Anzueto, Marc Miravitlles, Pierre Arvis, Jeff Alder, Daniel Haverstock, Mila Trajanovic and Sanjay Sethi. Eur Respir J 2012; 40: 17–27.},
Source: Eur Respir J 2012; 40: 800
Year: 2012


“Balloon pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension: is Europe behind?” Irene M. Lang and Hiromi Matsubara. Eur Respir J 2019; 53: 1900843.
Source: Eur Respir J, 54 (4) 1950843; 10.1183/13993003.50843-2019
Year: 2019


“RESPIRE: breathing new life into bronchiectasis.” Sanjay H. Chotirmall and James D. Chalmers. Eur Respir J 2018; 51: 1702444.
Source: Eur Respir J, 51 (2) 1752444; 10.1183/13993003.52444-2017
Year: 2018